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Abstract
Background. Serum cytokines are increased in patients
with acute kidney injury (AKI) and predict increased mor-
tality. It is widely assumed that increased renal production
of cytokines is the source of increased serum cytokines;
the role of extra-renal cytokine production and impaired
renal cytokine clearance is less well studied. We hypoth-
esized that cytokine production in AKI was mononuclear
phagocyte dependent, independent of production by the
kidneys, and that serum cytokine clearance would be im-
paired in AKI.
Methods. Bilateral nephrectomy was used as a model
of AKI to assess cytokine production independent of
kidney cytokine production. Mononuclear phagocytes
were depleted utilizing intravenous (IV) administration
of liposome-encapsulated clodronate (LEC). Twenty-
three serum cytokines were determined utilizing a multi-
plex cytokine kit. Proteins for cytokines were deter-
mined in the spleen and liver by enzyme-linked
immunosorbent assay. Recombinant cytokines were in-
jected by IV into mice with bilateral nephrectomy to de-
termine the effect of absent kidney function on serum
cytokine clearance.
Results. Serum interleukin (IL)-6, chemokine (C-X-C
motif ) ligand 1 (CXCL1), IL-10, IL-1β, monocyte che-
motactic protein 1 (MCP-1), IL-5 and eotaxin were in-
creased in the serum of mice after bilateral nephrectomy
and were reduced with LEC. Serum IL-12p40 and regu-
lated upon activation, normal T-cell expressed, and
secreted (RANTES) were increased after bilateral ne-
phrectomy and were further increased with LEC. Spleen
IL-6, CXCL1, IL-10 and IL-1β and liver IL-6 and IL-
10 were increased after bilateral nephrectomy. After IV
injection, IL-6, CXCL1, IL-10 and IL-1β had a pro-
longed serum cytokine appearance in mice with bilateral
nephrectomy versus sham operation.
Conclusions. Increased mononuclear phagocyte pro-
duction and impaired renal clearance contribute to
serum cytokine accumulation in AKI, independent of
kidney injury. The effect of AKI on cytokine production
and clearance may contribute to the increased mortality
of patients with AKI.
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Introduction
Serum cytokines are increased in patients with acute
kidney injury (AKI), and increased serum interleukin
(IL)-6, IL-8 and IL-10 predict mortality in patients with
AKI [1]. Cytokines are not just biomarkers of poor out-
comes, but mediate deleterious systemic effects. Pro-
inflammatory cytokines such as IL-6 and IL-8 mediate
distant organ injury and contribute to the systemic
inflammatory response syndrome and acute lung injury
(ALI). Anti-inflammatory cytokines such as IL-10 may
contribute to immune stasis and impair the ability to
fight infection. These cytokine-mediated deleterious
effects may contribute to the high mortality of patients
with AKI. Thus, a better understanding of the pro-
duction and clearance of cytokines in AKI may shed
light onto potential therapeutic treatments for patients
with AKI.
The role of the kidneys in cytokine production after
AKI is well described in animal models of AKI [2–3].
Less well studied is the contribution that extra-renal cyto-
kine production and impaired renal cytokine clearance
may have on serum cytokine accumulation in AKI. We
have previously demonstrated that certain cytokines are
increased in the serum after bilateral nephrectomy [2], a
model of acute renal failure without kidneys. Since
kidney production of cytokines cannot explain increased
serum cytokines after bilateral nephrectomy, we hypoth-
esized that other mechanisms of serum cytokine accumu-
lation may occur in AKI.
© The Author 2012. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
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Mononuclear phagocytes, known as monocytes when
in the blood and macrophages when in tissues, are a key
source of cytokine production after a variety of insults.
Mononuclear phagocytes mediate AKI, and the depletion
of mononuclear phagocytes with liposome-encapsulated
clodronate (LEC) protects against ischemic AKI and
reduces renal cytokine production [4–6]. The role of
mononuclear phagocytes, independent of the kidney, in
cytokine production in AKI is unknown.
In the present study, therefore, we hypothesized that
cytokine production in AKI is mononuclear phagocyte
dependent, independent of production by the kidneys, and
that serum cytokine clearance is impaired in AKI. In
order to test this hypothesis, we depleted mononuclear
phagocytes by intravenous (IV) injection of LEC, bilateral
nephrectomy was performed and serum cytokines were
determined. To determine the effect of absent kidney
function on serum cytokine clearance, recombinant cyto-
kines were injected by IV into mice with bilateral ne-
phrectomy and serum cytokines were measured.
Materials and methods
Mice
For all the mouse studies, 8- to 10-week-old C57BL/6 mice (Jackson
Labs, Bar Harbor, ME) weighing 20–25 g were used. Mice were main-
tained on a standard diet and water was freely available. All experiments
were conducted with adherence to the NIH Guide for the Care and Use
of Laboratory Animals. The animal protocol was approved by the
Animal Care and Use Committee of the University of Colorado Health
Sciences Center.
Sham operation and bilateral nephrectomy protocol
Mice were anesthetized with an intraperitoneal injection of avertin
(2,2,2-tribromoethanol: Aldrich, Milwaukee, WI). For bilateral nephrect-
omy, a midline incision was made and the renal pedicles were tied off
with suture and then cut distally. The ureters were pinched off with
forceps and the kidneys removed. The bilateral nephrectomy model is
well established in our laboratory [2, 7]. Sham surgery consisted of the
same procedure except that the renal pedicles were not tied off and the
kidneys were not removed.
Assessment of renal function
Blood urea nitrogen (BUN) and serum creatinine were measured using a
QuantiChrom assay kit (BioAssay Systems, Hayward, CA).
Lung CXCL1
Lung CXCL1 was performed on whole lung homogenates by enzyme-
linked immunosorbent assay (ELISA; R&D Systems, Minneapolis, MN)
and corrected for protein. The detection limit is 2.0 pg/mL. Tissue was
prepared as described previously [7].
Lung myeloperoxidase activity
One-fourth of the lung was homogenized as described previously [7].
Cytokine injection
Mice underwent sham operation or bilateral nephrectomy. Immediately
after surgery, 200 ng of recombinant murine IL-6, CXCL1, IL-10 or IL-
1β (Peprotech) in 100 µL of phosphate-buffered saline (PBS) with 0.1%
bovine serum albumin was administered intravenously. Vehicle-treated
mice received 100 µL of PBS with 0.1% bovine serum albumin. Blood
was collected by cardiac puncture 60 min after receiving IV cytokine or
vehicle.
Mononuclear phagocyte depletion
LEC and empty liposomes were purchased from Encapsula NanoS-
ciences (Nashville, TN). Mice received a tail vein injection of 10 µg of
vehicle (empty liposomes) or LEC in 100 µL sterile PBS at 5 and 2 days
before sham operation or bilateral nephrectomy.
Serum cytokine measurement
Blood samples were obtained at sacrifice via cardiac puncture. To assure
uniformity of serum samples, all samples were processed in the same
manner as we have described previously [2, 7]. Twenty-three cytokines
[IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (p40), IL-
12 (p70), IL-13, IL-17, eotaxin, granulocyte colony-stimulating factor,
granulocyte macrophage colony-stimulating factor, interferon-γ, KC,
MCP-1, macrophage inflammatory protein 1 (MIP-1)α, MIP-1β,
RANTES and tumor necrosis factor (TNF)-α] were determined on
serum samples using a bead-based multiplex cytokine kit (Bio-Rad Lab-
oratories Inc., Hercules, CA) in conjunction with flow-based protein de-
tection and the Luminex LabMAP multiplex system (Luminex Corp.,
Austin, TX) according to the manufacturer’s direction. The detection
limit for each cytokine was 1.95 pg/mL.
Spleen and liver cytokine measurement by ELISA
The frozen spleen or liver was homogenized on ice in 500 µL of PBS
that contained 1% protease inhibitor cocktail (Sigma, St Louis, MO). A
total of 125 µL of 5% Triton X in PBS was added, and samples were
vortexed, frozen and thawed, and incubated on ice for 20 min. Samples
were centrifuged at 4°C at 14 000 g for 15 min. Supernatants were ana-
lyzed for protein content using a Bio-Rad DC protein assay kit. Super-
natants were analyzed for CXCL1/KC, IL-6, IL-10, IL-1β and TNF-α by
ELISA (R&D Systems).
Flow cytometry
Multicolor multiparameter flow cytometry was performed using a FACS-
Canto II instrument (BD Biosciences) compensated with single fluoro-
chromes and analyzed using Diva™ software (BD Biosciences). Freshly
isolated cells from the spleen (1–2 × 106) were stained for cell surface
antigen expression by incubating with antibodies at 4°C for 30 min in
the dark, washed twice in 2 mL PBS containing 1% bovine serum
albumin and 0.01% sodium azide (FACS Wash). The cells were washed
with FACS buffer and stained for cell surface markers before fixation in
PBS/1% paraformaldehyde for 15–20 min on ice. The following anti-
bodies were used: F4/80-APC and CD11b-PE (eBiosciencies), CD45-
V500 and Ly6G-APCCy7 (BD Pharmingen). Cells were gated according
to the size and scatter to eliminate dead cells and debris from analysis.
Statistical analysis
All values are expressed as mean ± SE. Non-parametric t-tests were per-
formed for the following experimental groups: sham operation versus
bilateral nephrectomy and bilateral nephrectomy versus bilateral ne-
phrectomy plus LEC. For cytokine injection experiments, non-parametric
t-tests were performed for the following: sham plus vehicle versus sham
plus cytokine; one-way ANOVA with the Dunnet post-test analysis with
bilateral nephrectomy plus cytokine as the control group was performed.
For t-tests, groups with significant variance were subjected to Welch’s
correction. Avalue of P < 0.05 was considered statistically significant.
Results
IV administration of LEC reduces splenic mononuclear
phagocytes
IV LEC is known to result in the systemic depletion of
circulating monocytes and resident mononuclear phago-
cytes in the spleen and liver. To confirm mononuclear
phagocyte depletion with administration in the setting of
bilateral nephrectomy, flow cytometry was performed. As
shown in Figure 1, IV LEC administration to mice 5 and
2 days before sham operation and bilateral nephrectomy
resulted in a significant reduction in splenic mononuclear
phagocytes defined as CD45-positive, F4/80-positive and
Ly6G-negative cells.
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Serum IL-6, CXCL1, IL-10, IL-1β, MCP-1, IL-5
and eotaxin are increased after bilateral nephrectomy
and reduced with LEC administration
To examine the role of mononuclear phagocyte pro-
duction of cytokines in AKI, 23 serum cytokines were de-
termined in mice 4 h after sham operation or bilateral
nephrectomy with or without IV LEC administration
(Table 1). Of the 23 serum cytokines measured, 10 were
increased after bilateral nephrectomy compared with sham
operation: IL-6, CXCL1, IL-10, IL-1β, MCP-1, IL-5,
eotaxin, IL-12 (p40), RANTES and G-CSF. Of these,
seven were reduced with LEC (IL-6, CXCL1, IL-10, IL-
1β, MCP-1, IL-5 and eotaxin) (Figure 2) and two were
increased with LEC administration [IL-12 (p40) and
RANTES] (Figure 3). LEC did not have a significant
effect on serum G-CSF after bilateral nephrectomy (data
not shown). None of the other cytokines measured
showed significant differences between sham operation
versus bilateral nephrectomy or bilateral nephrectomy
versus bilateral nephrectomy plus LEC. Confirmatory
ELISA for serum IL-6 was performed and similar results
were obtained as results for IL-6 determined by the
Luminex method (data not shown).
Renal function was assessed after bilateral nephrectomy
with administration of IV LEC or vehicle and no signifi-
cant changes were found in serum creatinine and BUN.
Specifically, serum creatinine was 1.28 ± 0.15 mg/dL in
bilateral nephrectomy plus vehicle and 1.22 ± 0.17 mg/dL
in bilateral nephrectomy plus LEC (P = NS, n = 5–8).
BUN was 60 ± 5.1 mg/dL in bilateral nephrectomy plus
vehicle and 53 ± 6.8 mg/dL in bilateral nephrectomy plus
LEC (P = NS, n = 5–8).
We have previously shown that lung inflammation
occurs by 2 h after bilateral nephrectomy [7]. To deter-
mine whether administration of LEC has an effect on lung
inflammation, lung myeloperoxidase (MPO) activity,
which is a marker of neutrophil infiltration, and lung
CXCL1 (a neutrophil chemokine) were assessed 2 h after
sham surgery and bilateral nephrectomy with adminis-
tration of LEC or vehicle. Lung inflammation was not
reduced after LEC treatment compared with vehicle after
bilateral nephrectomy or sham operation. Specifically,
lung MPO activity was 0.475 ± 0.1 Δ/min/mg in sham
Fig. 1. IV administration of LEC reduces splenic mononuclear phagocytes. Sham operation (Sham) or bilateral nephrectomy (BNx) was performed
with or without administration of LEC. Flow cytometry was performed to confirm mononuclear phagocyte depletion. IV LEC administration to
before sham operation and bilateral nephrectomy resulted in a significant reduction in splenic mononuclear phagocytes defined as CD45-positive, F4/
80-positive and Ly6G-negative cells (n = 4–7).
Table 1. Summary of serum cytokine results after bilateral nephrectomy








IL-12 (p40) ↑ ↑
RANTES ↑ ↑
G-CSF ↑ =
Twenty-three serum cytokines were determined after bilateral
nephrectomy and bilateral nephrectomy with LEC treatment.
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plus vehicle and 0.65 ± 0.103 (Δ/min/mg) in sham plus
LEC (P = NS, n = 5–8) and was 1.44 ± 0.22 (Δ/min/mg)
in bilateral nephrectomy plus vehicle and 1.52 ± .16
(Δ/min/mg) in bilateral nephrectomy plus LEC (P = NS,
n = 5–8). Lung CXCL1 was 2723. ± 54.7 pg/mg in sham
plus vehicle and 219 ± 75.2 pg/mg in sham plus LEC
(P = NS, n = 5–8) and was 438 ± 58.7 pg/mg in bilateral
nephrectomy plus vehicle and 409 ± 43.6 pg/mg in bilat-
eral nephrectomy plus LEC (P = NS, n = 5–8). Since we
have previously demonstrated that IL-6 is an important
mediator of lung inflammation after bilateral nephrectomy
[7], we speculate that the reduction in serum IL-6 with
LEC, while significant, was insufficient to prevent the
development of lung inflammation after bilateral
Fig. 2. Serum IL-6, CXCL1, IL-10, IL-1β, IL-5, MCP-1 and eotaxin were increased after bilateral nephrectomy and reduced with LEC treatment.
Sham operation (Sham) or bilateral nephrectomy (BNx) was performed with or without administration of LEC to deplete mononuclear phagocytes.
Serum (A) IL-6, (B) CXCL1, (C) IL-10, (D) IL-1β, (E) IL-5, (F) MCP-1 and (G) eotaxin were all increased in mice with bilateral nephrectomy
versus sham operation and reduced with LEC treatment. *P < 0.05 versus Sham,**P < 0.01 versus Sham, #P < 0.05 versus BNx, ##P < 0.01 versus
BNx (n = 4–7).
Fig. 3. Serum IL-12 (p40) and RANTES were increased after bilateral nephrectomy and further increased with LEC treatment. Sham operation
(Sham) or bilateral nephrectomy (BNx) was performed with or without administration of LEC to deplete mononuclear phagocytes. Serum (A) IL-12
(p40) and (B) RANTES were both increased in mice with bilateral nephrectomy versus sham operation and were further increased with LEC
treatment. **P < 0.01 versus Sham, ##P < 0.01 versus BNx (n = 4–7).
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nephrectomy. Furthermore, we have demonstrated that al-
veolar macrophages are important in CXCL1 production
and neutrophil accumulation after ischemic AKI; alveolar
macrophages are not depleted with IV LEC and may thus
also contribute to lung inflammation after bilateral ne-
phrectomy [8]. Indeed, mononuclear phagocytes are
likely to have a complex role in the development of lung
inflammation after AKI.
Protein for IL-6, CXCL1, IL-10, IL-1β and TNF-α in the
spleen and liver after bilateral nephrectomy
Proteins for IL-6, CXCL1, IL-10, IL-1β and TNF-α were
determined by ELISA in the spleen and liver 2 h after
sham operation or bilateral nephrectomy. As shown in
Figure 4, IL-6, CXCL1, IL-10 and IL-1β were increased
in the spleen 2 h after bilateral nephrectomy versus sham;
IL-6 and IL-10 were also significantly increased in the
liver 2 h after bilateral nephrectomy versus sham. TNF- α
did not increased in the liver or spleen after bilateral
nephrectomy.
To determine whether administration of LEC would
influence cytokine production, proteins for IL-6, CXCL1,
IL-10, IL-1β and TNF-α were determined by ELISA in
the spleen and liver 2 h after bilateral nephrectomy with
LEC or vehicle administration. As shown in Figure 5, we
found a reduction in IL-6 and CXCL1 production 2 h
after bilateral nephrectomy and LEC administration com-
pared with vehicle in the spleen, but no change in these
cytokines was found in the liver. IL-1β was reduced in the
liver after bilateral nephrectomy and LEC administration
compared with vehicle with no significant change in the
spleen. No change in IL-10 or TNF-α production was
found in the spleen or liver after bilateral nephrectomy
with or without LEC administration.
Injection of cytokines to mice with bilateral nephrectomy
To determine whether lack of kidney function resulted in
delayed serum cytokine clearance in mice with bilateral
nephrectomy, 200 ng of IL-6, CXCL1, IL-10, IL-1β,
TNF-α or vehicle was administered by tail vein injection
Fig. 4. IL-6, CXCL1 and IL-10 protein are increased in the spleen 2 h after bilateral nephrectomy. Sham operation (Sham) or bilateral nephrectomy
(BNx) was performed, and (A) IL-6, (B) IL-10, (C) CXCL1, (D) IL-1β and (E) TNF-α were measured in the spleen and liver by ELISA 2 h post-
procedure. IL-6 and IL-10 were significantly increased in both organs. CXCL1 and IL-1β was significantly increased in the spleen but not the liver.
TNF-α did not increase in either organ (n = 5–8).
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immediately after surgery to sham-operated mice or mice
with bilateral nephrectomy, and serum cytokine levels
were determined 1 h post-injection.
As shown in Figure 6, the injection of a cytokine to
sham-operated mice resulted in a detectable and signifi-
cant increase in the cytokine versus vehicle injection.
These data demonstrate that even with normal kidney
function, the dose of cytokine injection was not able to be
completely cleared from the serum within 1 h. For IL-6,
CXCL1, IL-10 and IL-1β, serum cytokine levels greater
than 2-fold higher were detected in the setting of bilateral
nephrectomy versus sham operation. As shown in
Figure 7, bilateral nephrectomy did not affect the serum
clearance of TNF-α.
Discussion
AKI complicates ∼20% of hospital admissions [9] and
30–50% of intensive care unit admissions [10]. AKI
confers an independent, excess risk of mortality [11–15],
regardless of whether the AKI is mild [16–17] or requires
renal replacement therapy [18–19]. The high mortality
associated with AKI suggests that there are deleterious
systemic effects of AKI which are potentially fatal.
Clinical and experimental data are mounting that AKI
causes widespread distant organ injury [20–21] and pro-
inflammatory cytokines have been shown in animal
models to mediate lung, gastrointestnal, cardiac and brain
injury after AKI [2, 22–24]. In patients, the role of pro-
inflammatory cytokines in mediating distant organ injury,
ALI and multiple organ dysfunction syndrome is well de-
scribed [25–26]. The pro-inflammatory response is typi-
cally followed by an anti-inflammatory response known
as the compensatory anti-inflammatory response syn-
drome [27]. Clinical and experimental data indicate that
an anti-inflammatory response also occurs in AKI charac-
terized by increased splenic and hepatic IL-10 production
[28–29] and increased serum IL-10 [1–2, 28]. Although
IL-10 may be necessary to counter the pro-inflammatory
response after AKI, excess IL-10 may impair infection
fighting ability and it is well known that infection is a key
cause of death in patients with AKI [30–31]. Thus, both
pro- and anti-inflammatory cytokines may contribute to
the increased mortality observed in patients with AKI.
Supporting this notion are clinical data demonstrating that
Fig. 5. IL-6 and CXCL1 are reduced in the spleen 2 h after bilateral nephrectomy and LEC. Bilateral nephrectomy (BNx) with LEC or Vehicle
administration was performed, and (A) IL-6, (B) IL-10, (C) CXCL1, (D) IL-1β and (E) TNF-α were measured in the spleen and liver by ELISA 2 h
post-procedure. IL-6 and CXCL1 were significantly decreased in the spleen after LEC treatment. IL-1β was significantly decreased in the liver after
LEC treatment. IL-10 and TNF-α did not change in either organ (n = 5–8).
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serum IL-6, IL-8 and IL-10 are increased and predict in-
creased morality in patients with AKI [1].
Serum cytokines may accumulate in AKI through
many mechanisms including increased renal production,
increased extra-renal production and impaired renal clear-
ance. Since AKI is characterized by injury to kidney
tissue, it has been presumed that renal cytokine pro-
duction from injury—whether ischemic or nephrotoxic—
is the inciting event which leads to serum cytokine
accumulation. Indeed, mRNA or protein of multiple cyto-
kines has been demonstrated in the kidney after ischemic
or cisplatin-induced AKI [2–3, 32–33].
In the present study, we sought to determine whether
serum cytokine accumulation in AKI was ‘independent’
of injured kidney tissue and we therefore studied cytokine
production and clearance after bilateral nephrectomy, a
model of acute renal failure without kidney injury. Our
novel data demonstrate that mononuclear phagocytes
mediate serum cytokine accumulation, independent of
injured kidney.
To examine the role of mononuclear phagocytes in cy-
tokine production after AKI, independent of renal cyto-
kine production, we administered IV LEC to mice with
bilateral nephrectomy. The use of LEC is a well-described
strategy to deplete mononuclear phagocytes [34–37],
although dendritic cells are also depleted with this strat-
egy [38–40]. Mononuclear phagocytes and dendritic cells
ingest the liposomes causing death via apoptosis; cell
death occurs without cytokine release. The population of
cells depleted depends on the route of administration; IV
LEC, as used in this study, reduces mononuclear
phagocytes from the bone marrow, blood, liver and spleen
[34, 41].
Our data in the present study suggest that mononuclear
phagocytes and dendritic cells not derived from the
kidney contribute extensively to the systemic inflamma-
tory state of AKI. Of the 10 cytokines that increased after
bilateral nephrectomy, 7 (IL-6, CXCL1, IL-10, IL-1β,
MCP-1, IL-5 and eotaxin) were reduced with LEC treat-
ment. These data are consistent with what is known in
patients with end-stage kidney failure in whom extra-renal
cytokine production occurs in part due to the uremic
environment [42]. For example, stimulated monocytes
from end-stage renal disease patients produce excess
IL-10 [43]. In contrast, the expression of RANTES and
IL-12(p40) was further increased with LEC treatment.
One can speculate that mononuclear phagocytes and/or
dendritic cells are responsible for the secretion of soluble
factors that may inhibit the production of RANTES and
IL-12p40 after bilateral nephrectomy.
Fig. 6. Serum clearance of IL-6, CXCL1, IL-10 and IL-1β is impaired in mice with bilateral nephrectomy. Vehicle (Veh) or 200 ng of (A) IL-6, (B)
CXCL1, (C) IL-10 or (D) IL-1β were administered intravenously by tail vein injection to mice immediately after sham operation (Sham) or bilateral
nephrectomy (BNx). Serum cytokine levels were determined 60 min post-injection. *P < 0.05 versus Sham + Veh; **P < 0.05 versus all other groups
(n = 3–7).
Fig. 7. Serum clearance of TNF-α is not affected by bilateral
nephrectomy. Vehicle (Veh) or 200 ng of TNF-α was administered
intravenously by tail vein injection to mice immediately after sham
operation (Sham) or bilateral nephrectomy (BNx). Serum cytokine levels
were determined 60 min post-injection. *P < 0.05 versus Sham + Veh;
NS, not significant versus Sham + TNF-α (n = 4–10).
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In light of our data, it seems possible that the uremic
environment of ‘acute’ renal failure is also a stimulus for
mononuclear phagocyte cytokine production. Indeed, pro-
ducts normally cleared by the kidney accumulate rapidly
as judged by the 3-fold increase in BUN just 4 h after
bilateral nephrectomy; thus, some factor(s) normally
cleared by the kidney may be the stimulus for mono-
nuclear phagocyte/dendritic cell cytokine production after
AKI.
To further assess cytokine production after bilateral ne-
phrectomy, proteins for IL-6, CXCL1, IL-10, IL-1β and
TNF-α were determined in the liver and spleen. All
except TNF-α were found to be increased in the spleen 2
h after bilateral nephrectomy, and IL-6, CXCL1 and IL-
10 were also increased in the liver 2 h after bilateral ne-
phrectomy. LEC treatment decreased splenic IL-6 and
CXCL1 production and hepatic IL-1β. We chose to
examine these five cytokines as they are the most clini-
cally relevant in patients with AKI and critical illness in
general. All of these cytokines have been shown to be in-
creased in the serum of patients with AKI [1].
Pharmacokinetic studies have demonstrated that the
kidney plays a role in cytokine clearance via filtration and
proximal tubule metabolism [44–45]. Other key mechan-
isms of cytokine clearance are liver metabolism and cyto-
kine binding to a specific cytokine receptor. Several other
organs such as the gut, spleen and lungs have an
additional but small catabolic role [46]. Generally, it has
been observed that the kidney accounts for ∼15–20% cy-
tokine metabolism versus other mechanisms of clearance.
For example, in a study in which normal rats were in-
jected with radiolabelled IL-10, 23% accumulated in the
kidney, 11% in the liver and less than 5% in other organs
and urine [47]. In another study, also performed in normal
rats, radiolabelled IL-6 was injected and 80% accumulated
in the liver and 15% in the kidney [48]. Whether impaired
renal metabolism has any meaningful effect on serum cy-
tokine accumulation, however, has not been well studied.
We [49] and others [50] have reported serum cytokine
accumulation after cytokine injection to mice with bilat-
eral nephrectomy; however, these studies were done utiliz-
ing recombinant ‘human’ forms of IL-6 and IL-10 to
mice. Human, rat and mouse cytokines do not have a
100% homology; in fact, human and rat IL-6 and IL-10
only share 39 and 74% homology, respectively, at the
protein sequence level. Therefore, impaired clearance in
these studies could represent non-specific impaired clear-
ance of a foreign protein.
Thus, in the present study, we tested whether absent
kidney function had a direct effect on serum cytokine
accumulation by injecting recombinant murine forms of
IL-6, CXCL1, IL-10, IL-1β or TNF-α to mice with bilat-
eral nephrectomy. We demonstrate that absent kidney
function has a significant effect on IL-6, CXCL1, IL-10
and IL-1β accumulation in the serum, with values 2-fold
higher in bilateral nephrectomy compared with sham-op-
erated mice; these data are especially clinically relevant as
these cytokines are increased in the serum of patients with
AKI and suggest that absent kidney function does indeed
affect serum cytokine accumulation. IL-6, CXCL1
(analog of human IL-8) and IL-10 are particularly
relevant to patients with AKI as their increase is associ-
ated with increased mortality [1]. Interestingly, we were
not able to demonstrate that absent kidney function
affected serum cytokine accumulation for TNF-α,
suggesting that intact kidney function is not as necessary
for TNF-α elimination as it is for the other cytokines
examined in our study.
Together with what is already known regarding cyto-
kine metabolism and production, our data suggest that
AKI has the following effects on cytokines: (i) increased
renal cytokine production, (ii) increased extra-renal cyto-
kine production, (iii) increased mononuclear phagocyte
cytokine production and (iv) impaired renal cytokine
clearance. Furthermore, these factors work together to
cause serum cytokine accumulation in AKI. Higher levels
of serum cytokines are associated with adverse outcomes
in AKI such as prolonged mechanical ventilation [51] and
increased mortality [1]. Serum cytokine accumulation
may simply reflect worse AKI and thus be the explanation
for worse outcomes; alternatively, serum cytokines may
have adverse distant organ effects and may thus directly
contribute to organ injury and increased mortality in AKI.
In conclusion, we demonstrate that serum cytokines in-
crease during AKI due to increased mononuclear phago-
cyte production and impaired renal clearance,
independent of kidney injury. Since higher levels of
serum cytokines are associated with adverse outcomes in
patients with AKI, further study of the deleterious effects
of circulating cytokines in AKI may hold the key to redu-
cing the increased mortality of patients with AKI.
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